查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591807

基因检测市场：按疾病类型、技术、应用和最终用户划分 - 全球预测 2025-2030

Hereditary Testing Market by Disease Type (Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening), Technology (Biochemical, Cytogenetic, Molecular Testing), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

基因检测市场2023年估值为51.5亿美元，预计2024年将达55.7亿美元，复合年增长率为8.17%，预计到2030年将达到89.3亿美元。

基因检测也称为基因检测，透过分析DNA来识别基因、染色体和蛋白质的变化，以帮助检测遗传性疾病。基因检测的范围包括诊断、预测、带因者检测、产前筛检和新生儿筛检。这项需求是由对早期疾病检测、个人化医疗和公众对遗传疾病认识不断提高的需求不断增长所推动的。此测试可应用于肿瘤学、心臟病学和神经学等多个领域，可供医疗保健专业人员、患者和研究人员使用。市场成长主要受到次世代定序、政府资助增加和遗传病患病率上升等技术进步的影响。个人化医疗在新兴市场的扩张存在着商机，而人工智慧用于资料分析和解释的整合可以提高测试的准确性和速度。抓住这些机会的建议包括投资研发以提高测试准确性和可负担性，并促进与医疗保健提供者的合作以实现更广泛的覆盖范围。

主要市场统计
基准年[2023] 51.5亿美元
预测年份 [2024] 55.7亿美元
预测年份 [2030] 89.3亿美元
复合年增长率（%） 8.17%

然而，市场面临挑战，包括监管障碍、有关基因隐私的道德担忧以及潜在的保险范围限制。克服这些限制需要强有力的资料隐私措施和公共教育倡议，以减轻道德担忧。创新成长领域包括非侵入性产前检测、扩展到药物基因组学以及开发直接面向消费者的检测套组。市场充满活力，竞争激烈，技术进步迅速，需要不断创新与适应。公司可以透过策略伙伴关係和行销宣传活动来重点提高负担能力和意识。总体而言，利用技术和医疗保健的交叉点对于利用蓬勃发展的基因检测市场至关重要。

市场动态：揭示快速发展的基因检测市场的关键市场洞察

供需的动态交互作用正在改变基因检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 探索 DNA 变化和变异以找到疾病的潜在根源
    • 增加孕妇筛检
    • 活性化基因组定序的研发活动
  • 市场限制因素
    • 有限报销政策
  • 市场机会
    • 联合产品开发
    • 价值链内有吸引力的投资和併购活动
  • 市场挑战
    • 基因检测结果不确定

波特五力：驾驭基因检测市场的策略工具

波特的五力架构是了解基因检测市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基因检测市场的外部影响

外部宏观环境因素在塑造基因检测市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解基因检测市场的竞争格局

对基因检测市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵基因检测市场供应商绩效评估

FPNV定位矩阵是评估基因检测市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划基因检测市场的成功之路

基因检测市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 研究 DNA 的变化和突变，找出潜在疾病的根本原因
      • 增加孕妇筛检测试
      • 活性化与基因组序列分析的进步相关的研究开发活动
    • 抑制因素
      • 有限退费政策
    • 机会
      • 联合产品开发
      • 价值链内有吸引力的投资和併购活动
    • 任务
      • 基因检测结果不确定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 基因检测市场：依疾病类型

  • 遗传性癌症检测
    • 乳癌
    • 子宫颈癌
    • 大肠直肠癌
    • 肺癌
    • 恶性黑色素瘤
    • 卵巢癌
    • 胰臟癌
    • 摄护腺癌
    • 肉瘤
    • 胃癌
    • 子宫癌
  • 遗传性非癌症检测
    • 基因检测
      • 心臟病
      • 罕见疾病
  • 新生儿基因筛检
  • 无创产前检测和带因者筛检测试
  • 胚胎着床前遗传诊断与筛检

第七章 基因检测市场：依技术分类

  • 生化
  • 细胞遗传学
  • 分子检测

第八章 基因检测市场：依应用分类

  • 癌症诊断
  • 心血管疾病的诊断
  • 遗传性疾病的诊断

第九章 基因检测市场：依最终使用者分类

  • 诊所
  • 医院

第十章美洲基因检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太基因检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲基因检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • BGI Genomics Co., Ltd.
  • Biocartis NV
  • CENTOGENE NV
  • CooperSurgical, Inc.
  • CSL Behring
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Invitae Corporation
  • Konica Minolta, Inc.
  • Medgenome
  • Myriad Genetics, Inc.
  • Natera Inc.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • SOPHiA Genetics
Product Code: MRR-A339DAEFA85A

The Hereditary Testing Market was valued at USD 5.15 billion in 2023, expected to reach USD 5.57 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 8.93 billion by 2030.

Hereditary testing, also known as genetic testing, involves analyzing DNA to identify changes in genes, chromosomes, or proteins, helping detect genetic disorders. The scope of hereditary testing encompasses diagnostic, predictive, and carrier testing, as well as prenatal and newborn screening. Its necessity is driven by the increasing need for early disease detection, personalized medicine, and growing public awareness about genetic disorders. It is applied in various areas, including oncology, cardiology, and neurology, catering to healthcare professionals, patients, and researchers. Market growth is primarily influenced by technological advancements like next-generation sequencing, increased government funding, and a rising prevalence of genetic diseases. Opportunities lie in expanding personalized medicine within emerging markets, and the integration of AI for data analysis and interpretation can enhance testing accuracy and speed. Recommendations to seize these opportunities include investing in R&D to improve test accuracy and affordability, and fostering collaborations with healthcare providers for wider reach.

KEY MARKET STATISTICS
Base Year [2023] USD 5.15 billion
Estimated Year [2024] USD 5.57 billion
Forecast Year [2030] USD 8.93 billion
CAGR (%) 8.17%

However, the market faces challenges such as regulatory hurdles, ethical concerns surrounding genetic privacy, and potential insurance coverage limitations. Overcoming these limitations requires robust data privacy measures and public education initiatives to alleviate ethical concerns. Innovative areas for growth include non-invasive prenatal testing, expansion into pharmacogenomics, and the development of direct-to-consumer testing kits. The market is highly dynamic, characterized by increased competition and rapid technological advancements, necessitating continuous innovation and adaptation. Companies might focus on increasing affordability and awareness through strategic partnerships and marketing campaigns. Overall, leveraging the intersection of technology and healthcare will be crucial for capitalizing on the booming hereditary testing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hereditary Testing Market

The Hereditary Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Exploration for changes or variants, in DNA to find root cause of potential disease
    • Increased screening by pregnant women
    • Rising R&D activities on advance Genome sequencing
  • Market Restraints
    • Limited reimbursement policies
  • Market Opportunities
    • Collaborative product development
    • Attractive investment and amalgamation activity within value chain
  • Market Challenges
    • Uncertain outcomes of the hereditary testing

Porter's Five Forces: A Strategic Tool for Navigating the Hereditary Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hereditary Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hereditary Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hereditary Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hereditary Testing Market

A detailed market share analysis in the Hereditary Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hereditary Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hereditary Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hereditary Testing Market

A strategic analysis of the Hereditary Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Testing Market, highlighting leading vendors and their innovative profiles. These include BGI Genomics Co., Ltd., Biocartis NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Behring, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Invitae Corporation, Konica Minolta, Inc., Medgenome, Myriad Genetics, Inc., Natera Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, and SOPHiA Genetics.

Market Segmentation & Coverage

This research report categorizes the Hereditary Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening, Non-Invasive Prenatal Testing & Carrier Screening Tests, and Preimplantation Genetic Diagnosis & Screening. The Hereditary Cancer Testing is further studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Stomach or Gastric Cancer, and Uterine Cancer. The Hereditary Non-Cancer Testing is further studied across Genetic Tests. The Genetic Tests is further studied across Cardiac Diseases and Rare Diseases.
  • Based on Technology, market is studied across Biochemical, Cytogenetic, and Molecular Testing.
  • Based on Application, market is studied across Cancer Diagnosis, Cardiovascular Disease Diagnosis, and Genetic Disease Diagnosis.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
      • 5.1.1.2. Increased screening by pregnant women
      • 5.1.1.3. Rising R&D activities on advance Genome sequencing
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative product development
      • 5.1.3.2. Attractive investment and amalgamation activity within value chain
    • 5.1.4. Challenges
      • 5.1.4.1. Uncertain outcomes of the hereditary testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hereditary Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hereditary Cancer Testing
    • 6.2.1. Breast Cancer
    • 6.2.2. Cervical Cancer
    • 6.2.3. Colorectal Cancer
    • 6.2.4. Lung Cancer
    • 6.2.5. Melanoma
    • 6.2.6. Ovarian Cancer
    • 6.2.7. Pancreatic Cancer
    • 6.2.8. Prostate Cancer
    • 6.2.9. Sarcoma
    • 6.2.10. Stomach or Gastric Cancer
    • 6.2.11. Uterine Cancer
  • 6.3. Hereditary Non-Cancer Testing
    • 6.3.1. Genetic Tests
      • 6.3.1.1. Cardiac Diseases
      • 6.3.1.2. Rare Diseases
  • 6.4. Newborn Genetic Screening
  • 6.5. Non-Invasive Prenatal Testing & Carrier Screening Tests
  • 6.6. Preimplantation Genetic Diagnosis & Screening

7. Hereditary Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Biochemical
  • 7.3. Cytogenetic
  • 7.4. Molecular Testing

8. Hereditary Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Diagnosis
  • 8.3. Cardiovascular Disease Diagnosis
  • 8.4. Genetic Disease Diagnosis

9. Hereditary Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospitals

10. Americas Hereditary Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hereditary Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hereditary Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. BGI Genomics Co., Ltd.
  • 2. Biocartis NV
  • 3. CENTOGENE N.V.
  • 4. CooperSurgical, Inc.
  • 5. CSL Behring
  • 6. Eurofins Scientific SE
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Invitae Corporation
  • 9. Konica Minolta, Inc.
  • 10. Medgenome
  • 11. Myriad Genetics, Inc.
  • 12. Natera Inc.
  • 13. Quest Diagnostics Incorporated
  • 14. Siemens Healthineers AG
  • 15. SOPHiA Genetics

LIST OF FIGURES

  • FIGURE 1. HEREDITARY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HEREDITARY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEREDITARY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEREDITARY TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEREDITARY TESTING MARKET SIZE, BY STOMACH OR GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING & CARRIER SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BIOCHEMICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CYTOGENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CANCER DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. TURKEY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 330. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 332. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 333. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023